How LUTATHERA May Help
Clinical Trial Results for LUTATHERA
In a clinical trial, 229 people with midgut NETs who received LUTATHERA in combination with 30 mg of long-acting octreotide were compared with those who received 60 mg of long-acting octreotide alone.
Longer Progression-Free Survival (PFS) for Patients Treated With LUTATHERA
More people treated with LUTATHERA had their tumors shrink compared with people treated with 60 mg of long-acting octreotide alone
13% of people
in the LUTATHERA with 30 mg of long-acting octreotide group
Partial response (tumors shrink)a:
12% (14 of 116 people)
Complete response (tumors disappear)b:
1% (1 of 116 people)
4% of people
in the 60 mg of long-acting octreotide group
Partial response (tumors shrink)a:
4% (4 of 113 people)
Complete response (tumors disappear)b:
0% (0 of 113 people)
aTumors shrink to ≥30% from baseline.
bTumors disappear and cancerous lymph nodes shrink to <10 mm. The disappearance of any measurable tumors does not necessarily mean that the cancer is completely gone.
